Background Nivolumab was associated with higher rates of objective response than chemotherapy
in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma…

Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset of resistance …

Background Nivolumab and ipilimumab are immune checkpoint inhibitors that have been
approved for the treatment of advanced melanoma. In the United States, ipilimumab has also …

Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …

Background Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor
trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations…

Background The combination of cobimetinib with vemurafenib improves progression-free
survival compared with placebo and vemurafenib in previously untreated patients with BRAF …

Background Nivolumab monotherapy and combination nivolumab plus ipilimumab increase
proportions of patients achieving a response and survival versus ipilimumab in patients with …

Background The European Organisation for Research and Treatment of Cancer (EORTC)
1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients with resected …

PURPOSE We conducted the phase III double-blind European Organisation for Research
and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab …

Background Previously, findings from CheckMate 238, a double-blind, phase 3 adjuvant
trial in patients with resected stage IIIB–C or stage IV melanoma, showed significant …